Article Dans Une Revue Journal of Clinical Immunology Année : 2023

Type I interferonopathy due to a homozygous loss-of-inhibitory function mutation in STAT2

Résumé

Purpose STAT2 is both an effector and negative regulator of type I interferon (IFN-I) signalling. We describe the characterization of a novel homozygous missense STAT2 substitution in a patient with a type I interferonopathy. Methods Whole-genome sequencing (WGS) was used to identify the genetic basis of disease in a patient with features of enhanced IFN-I signalling. After stable lentiviral reconstitution of STAT2-null human fibrosarcoma U6A cells with STAT2 wild type or p.(A219V), we performed quantitative polymerase chain reaction, western blotting, immunofluorescence, and co-immunoprecipitation to functionally characterize the p.(A219V) variant. Results WGS identified a rare homozygous single nucleotide transition in STAT2 (c.656C > T), resulting in a p.(A219V) substitution, in a patient displaying developmental delay, intracranial calcification, and up-regulation of interferon-stimulated gene (ISG) expression in blood. In vitro studies revealed that the STAT2 p.(A219V) variant retained the ability to transduce an IFN-I stimulus. Notably, STAT2 p.(A219V) failed to support receptor desensitization, resulting in sustained STAT2 phosphorylation and ISG up-regulation. Mechanistically, STAT2 p.(A219V) showed defective binding to ubiquitin specific protease 18 (USP18), providing a possible explanation for the chronic IFN-I pathway activation seen in the patient. Conclusion Our data indicate an impaired negative regulatory role of STAT2 p.(A219V) in IFN-I signalling and that mutations in STAT2 resulting in a type I interferonopathy state are not limited to the previously reported R148 residue. Indeed, structural modelling highlights at least 3 further residues critical to mediating a STAT2-USP18 interaction, in which mutations might be expected to result in defective negative feedback regulation of IFN-I signalling.
Fichier principal
Vignette du fichier
s10875-023-01445-3.pdf (1.33 Mo) Télécharger le fichier
Origine Publication financée par une institution
Licence

Dates et versions

cea-04334216 , version 1 (14-12-2023)

Licence

Identifiants

Citer

Gaofeng Zhu, Mihaly Badonyi, Lina Franklin, Luis Seabra, Gillian I. Rice, et al.. Type I interferonopathy due to a homozygous loss-of-inhibitory function mutation in STAT2. Journal of Clinical Immunology, 2023, 43 (4), pp.808-818. ⟨10.1007/s10875-023-01445-3⟩. ⟨cea-04334216⟩
65 Consultations
29 Téléchargements

Altmetric

Partager

More